Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a ...

The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal and bulbar muscular atrophy, according to the manufacturer.In a press release ...

The weakening of the bulbar muscles affects chewing, speech and swallowing, with patients prone to choking or inhaling foods or liquids, resulting in airway infection.

Nido Biosciences announces a new publication in Neurology revealing clinically meaningful endpoints for Spinal and Bulbar Muscular Atrophy (SBMA).

NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease.

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients AnnJi Pharmaceutical Company Announces Positive Phase 1/2a ...